trending Market Intelligence /marketintelligence/en/news-insights/trending/5wwpxekywio6uzpgleozaw2 content esgSubNav
In This List

Sumitomo Dainippon in ¥3.7B deal for drug to treat central nervous disease

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Sumitomo Dainippon in ¥3.7B deal for drug to treat central nervous disease

Sumitomo Dainippon Pharma Co. Ltd. will pay up to ?3.7 billion for the right to develop a substance using JCR Pharmaceuticals Co. Ltd.'s technology.

The payment is made up of an unspecified upfront amount plus further consideration related to the achievement of certain milestones.

JCR's J-Brain Cargo blood-brain barrier penetration technology is used in creating therapeutic agents for central nervous system diseases, including JR-141, which is being studied as a treatment for Hunter syndrome.

Sumitomo Dainippon, which is based in Japan, will have the rights to market the substance in the country, as well as North America. It may opt to secure the rights to the drug in China as well.

JCR Pharmaceuticals, which is also based in Japan, will also receive royalties on the sales of the drug once it is commercialized.

As of Feb. 23, US$1 was equivalent to 106.64 Japanese yen.